Selenocysteine mediated hybrid antibody molecules

US8916159B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Christoph Rader · San Diego, US
• Thomas Hofer · Zürich, CH
• Terrence R. Burke, Jr. · Kirkwood, US
• Joshua D. Thomas · Natick, US

Key dates

• Filing date: Sep 30, 2009
• Grant date: Dec 23, 2014
• Expiry date: Jan 25, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides methods and compositions employing hybrid molecules of a synthetic molecule and antibody or antibody fragment comprising a selenocysteine residue, wherein the synthetic molecule is covalently linked to the antibody or antibody fragment at the selenocysteine residue. The invention also provides a composition comprising a hybrid molecule as described above and a pharmaceutically acceptable carrier. The invention further provides for methods of making the hybrid molecules, and methods of using the hybrid molecule described above to inhibit cell surface receptor binding.